Liberum appointed as Joint Corporate Broker and Financial Adviser to Sensyne Health plc

Sensyne is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts.

These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance.

Sensyne signed its first major deal with Bayer in July to accelerate the clinical development of new treatments for cardiovascular disease, and recently signed a deal with a Fortune 200 company to launch and scale its existing licenced products in the US.

Sensyne was admitted to the AIM Market of the London Stock Exchange (SENS.L) in August 2018, and is based in the Schrödinger Building, located on Oxford Science Park.

Liberum Team

Investment Banking – Bidhi Bhoma, Euan Brown, Will Hall

Research – Graham Doyle, Alistair Campbell

Sales – Seb Fernandez

CIR – Rosa Hibbert-Keene